Atea Pharmaceuticals (AVIR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Atea Pharmaceuticals

NasdaqGS•Healthcare•Biotechnology

$5.25-0.03(<0.01%)Market open

Market Cap

$425.07M

P/B

2.1x

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

How this company scores

WeakMetricSide Score: 37/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (6/25).

Profitability7/25

Growth9/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredNet cash positionImproving marginsNo share dilution

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 13.1x5y range 6.2x – 247.9x

Currently near its 5-quarter median.

P/S · 2.4x5y range 2.1x – 12.8x

Currently near its 5-quarter median.

P/B · 2.1x5y range 0.4x – 4.6x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $425.07M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-183.19M
TTM Op. Income: $-183.61M
Q. Op. Income: $-35.10M
TTM Net Income: $-165.29M
Q. Net Income: $-32.93M
EPS: $-0.41
Shares Out.: $80.05M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-183.19M and TTM operating income of $-183.61M show growth is flowing through to the bottom line. However, net income is negative at $165.29M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -3509900000.0%
Net Margin: -3293300000.0%

Op. margin of -3509900000.0% is up 624600000.0% YoY — cost efficiency is improving. Net margin at -3293300000.0% Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 2.1x

P/S of 0.0x and P/B of 2.1x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $232.28M
Cash: $76.55M
Long-Term Debt: N/A
Book Value: $204.16M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-37.08M
TTM Free Cash Flow: $-152.07M
FCF Margin: N/A
FCF / Net Income: 0.9

TTM FCF of $-152.07M on $-37.08M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.